Leuplin SR For Injection 11.25 MG



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Prostate Cancer Stage Iv 28.7%
Prostate Cancer Stage Ii 10.9%
Drug Use For Unknown Indication 9.0%
Hypertension 8.3%
Prostate Cancer Stage Iii 7.2%
Prostate Cancer 6.1%
Benign Prostatic Hyperplasia 5.2%
Constipation 3.3%
Diabetes Mellitus 3.2%
Gastritis 3.1%
Breast Cancer 2.2%
Cancer Pain 2.0%
Cardiac Failure 1.8%
Product Used For Unknown Indication 1.6%
Gastric Ulcer 1.5%
Angina Pectoris 1.2%
Dysuria 1.2%
Gastrointestinal Disorder 1.2%
Hyperlipidaemia 1.2%
Reflux Oesophagitis 1.1%
Prostate Cancer 20.8%
Prostate Cancer Stage Iv 12.4%
Interstitial Lung Disease 10.1%
Cerebral Infarction 7.0%
Lung Neoplasm Malignant 6.7%
Pneumonia 5.4%
Cardiac Failure 4.0%
Colon Cancer 3.4%
Gastric Cancer 3.4%
Spinal Compression Fracture 3.0%
Pollakiuria 2.7%
Prostatic Specific Antigen Increased 2.7%
Acute Myocardial Infarction 2.3%
Bladder Cancer 2.3%
Hepatic Function Abnormal 2.3%
Marasmus 2.3%
Pancreatic Carcinoma 2.3%
Platelet Count Decreased 2.3%
Urinary Retention 2.3%
Injection Site Induration 2.0%
Secondary
Prostate Cancer Stage Iv 25.9%
Prostate Cancer Stage Ii 10.1%
Prostate Cancer Stage Iii 9.2%
Hypertension 8.1%
Drug Use For Unknown Indication 7.2%
Benign Prostatic Hyperplasia 6.1%
Prostate Cancer 5.6%
Diabetes Mellitus 4.6%
Gastrointestinal Disorder 3.3%
Gastritis 3.2%
Product Used For Unknown Indication 3.2%
Constipation 2.5%
Neurogenic Bladder 1.8%
Breast Cancer 1.6%
Gastritis Prophylaxis 1.6%
Myocardial Infarction 1.6%
Pollakiuria 1.3%
Back Pain 1.1%
Dysuria 1.1%
Endometriosis 1.1%
Prostate Cancer 13.6%
Cerebral Infarction 10.0%
Lung Neoplasm Malignant 9.1%
Prostate Cancer Stage Iv 8.2%
Interstitial Lung Disease 6.4%
Prostatic Specific Antigen Increased 5.5%
Urinary Retention 5.5%
Marasmus 4.5%
Supraventricular Extrasystoles 4.5%
Fall 3.6%
Metastases To Lung 3.6%
Urinary Incontinence 3.6%
Acute Myocardial Infarction 2.7%
Gallbladder Perforation 2.7%
Hepatic Function Abnormal 2.7%
Hepatic Rupture 2.7%
Incorrect Dose Administered 2.7%
Metastases To Bone 2.7%
Metastases To Central Nervous System 2.7%
Pneumonia Aspiration 2.7%